Breaking Finance News

Zacks Investment Research downgraded Ionis Pharmaceuticals Inc (NASDAQ:IONS) to Sell in a report released today.

Just yesterday Ionis Pharmaceuticals Inc (NASDAQ:IONS) traded -0.45% lower at $29.00. Ionis Pharmaceuticals Inc’s 50-day moving average is $32.40 and its 200-day moving average is $31.86. The last closing price is down -9.39% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,254,823 shares of IONS traded hands, down from an average trading volume of 2,259,710

Zacks Investment Research has downgraded Ionis Pharmaceuticals Inc (NASDAQ:IONS) to Sell in a report released on Monday October 17, 2016.

Previously on 10/06/2016, BMO Capital Markets reported on Ionis Pharmaceuticals Inc (NASDAQ:IONS) increased the target price from $42.00 to $48.00. At the time, this indicated a possible upside of 0.32%.

Recent Performance Chart

Ionis Pharmaceuticals Inc (NASDAQ:IONS)

Ionis Pharmaceuticals Inc has 52 week low of $19.59 and a 52 week high of $65.34 and has a market capitalization of $0.

In addition to Zacks Investment Research reporting its target price, a total of 9 brokers have issued a report on the stock. The consensus target price is $52.56 with 1 broker rating the stock a strong buy, 5 brokers rating the stock a buy, 5 brokers rating the stock a hold, zero brokerages rating the company a underperform, and lastly one brokerage rating the company a sell.

General Company Details For Ionis Pharmaceuticals Inc (NASDAQ:IONS)

Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company's Ionis Core segment is developing a drug discovery platform. The Company's Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.